Appili Ther Stock Price, News & Analysis

Appili Therapeutics (OTCPink: APLIF), a biopharmaceutical company specializing in infectious diseases and biodefense drug development, held its annual and special meeting of shareholders with all proposed resolutions receiving approval.

The shareholders elected six directors to the board with overwhelming support, each receiving over 99% approval: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni, and Prakash Gowd. Additionally, shareholders approved the reappointment of PricewaterhouseCoopers as auditors, and endorsed the company's rolling 10% stock option plan and equity incentive plan.

Appili Therapeutics (OTC:APLIF) announced its participation in the NATO Chemical, Biological, Radiological and Nuclear Conference in Switzerland. Dr. Carl Gelhaus, Director of Non-Clinical Research, will present updates on ATI-1701, the company's first-in-class vaccine candidate for tularemia prevention.

The presentation will highlight preclinical data for ATI-1701, which is being developed with support from the U.S. Air Force Academy. The vaccine aims to address a critical gap in NATO's biodefense capabilities against Francisella tularensis, a highly infectious pathogen considered a top-priority biothreat. Currently, NATO forces lack specialized tularemia vaccines that are available to adversarial militaries.

Appili Therapeutics (OTC:APLIF), a biopharmaceutical company specializing in infectious diseases and medical countermeasures, reported its Q1 FY2026 financial results. The company has submitted seven U.S. government funding proposals totaling US$137 million and joined the U.S. Medical CBRN Defense Consortium.

Key developments include: LIKMEZ® re-launch in the U.S. market, progress on ATI-1701 tularemia vaccine development with US$11.6 million in USAFA funding, and advancement of ATI-1801 for leishmaniasis treatment. The company reported a reduced net loss of $1.2 million compared to $1.6 million in the previous year, with cash position of $1.1 million as of June 30, 2025.

Appili Therapeutics (OTC:APLIF) has published significant findings in the journal Vaccine demonstrating the effectiveness of ATI-1701, their biodefense vaccine candidate against tularemia. The study showed 100% survival rates in rats challenged with aerosolized F. tularensis SCHU S4, even at doses exceeding 10,000 times the median lethal dose.

The vaccine demonstrated up to 100% protection in cynomolgus macaques, with reduced disease severity and improved outcomes. ATI-1701, being developed in partnership with the U.S. Department of Defense, represents a first-in-class vaccine candidate for tularemia prevention, addressing an unmet need as there are currently no approved vaccines in major global markets.

Appili Therapeutics (OTC:APLIF) reported its fiscal year 2025 results and operational updates. Key highlights include the successful re-launch of LIKMEZ™, their FDA-approved liquid metronidazole oral suspension, with commercial sales ongoing. The company has submitted five U.S. government proposals totaling up to US$125 million in potential funding.

The company reported a reduced net loss of $2.6 million ($0.02 per share) compared to $3.8 million in FY2024. Cash position improved to $1.2 million as of March 31, 2025. Progress continues on key programs including ATI-1701 (tularemia vaccine) under US$11.6M USAF funding and ATI-1801 for leishmaniasis treatment, which received positive FDA feedback for development strategy.

Appili Therapeutics (TSX:APLI; OTCPink: APLIF) has published a significant manuscript in Frontiers in Bacteriology focusing on tularemia prevention. The publication, led by Dr. Carl Gelhaus and researchers from the United States Air Force Academy, examines immune responses to Francisella tularensis infections. The research directly supports the development of ATI-1701, Appili's biodefense vaccine candidate aimed at protecting warfighters from tularemia. The manuscript identifies key protection correlates and outlines promising pathways for vaccine development. Notably, ATI-1701 could become a first-in-class vaccine for tularemia prevention, addressing a critical gap as there are currently no approved vaccines in major global markets for this highly infectious pathogen.

Appili Therapeutics (TSX: APLI; OTCPink: APLIF) has secured new patents in the United States and Mexico for LIKMEZ, its oral formulation of metronidazole. The patents, expiring in 2039, protect the drug's unique taste-masked composition and therapeutic applications.

The U.S. patent (20230086660A1) and Mexican patent (2020007494) have been granted for 'Oral Formulations of Metronidazole and Methods of Treating an Infection Using Same.' Notably, Saptalis Pharmaceuticals, Appili's partner, has successfully listed the U.S. patent in the FDA's Orange Book.

Saptalis plans to re-launch LIKMEZ under its own label in May 2025. The drug's proprietary formulation offers improved stability and palatability, which are important factors for patient medication adherence and better treatment outcomes.

Appili Therapeutics (TSX: APLI; OTCPink: APLIF) announced that President and CEO Don Cilla will participate in Aditxt Weekly Update on April 4, 2025, alongside Aditxt CEO Amro Albanna. The discussion will focus on:

• The company's ongoing going-private transaction with Aditxt
• $117 million in new federal funding applications
• The growing threat of emerging infectious diseases
• Appili's near-to-market portfolio addressing unmet patient needs

The company highlighted its success in securing non-dilutive funding, including $33.2 million in prior government awards. The event will include a Q&A session, with Appili planning to participate in additional Aditxt Weekly Updates throughout the year.

Appili Therapeutics (APLIF) has submitted four new federal funding proposals totaling US$117.5 million to advance infectious disease treatments. Two proposals to NIAID seek US$46.3M for fungal infection vaccine development and US$36.4M for antifungal antibody development. Two additional proposals to MCDC request US$34.8M for viral infection treatments.

The company has joined the Medical CBRN Defense Consortium and received modifications to its USAFA Cooperative Agreement, including an increased G&A overhead recovery rate. However, due to budget constraints, no additional funds beyond the US$11.6M already allotted for ATI-1701 are expected, potentially delaying FDA submission.

The company's going-private transaction with Aditxt has been extended to March 31, 2025, with Aditxt providing a US$250,000 waiver payment.